Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.02, 9.01 · 8-K

Allarity Therapeutics, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Item 5.02(e) As previously disclosed, effective June 1, 2024, Allarity Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Management Services Agreement (the “Original MSA”) with Ljungaskog Consulting AB, a Swedish limited liability company (the “Consultant”), owned and managed by Thomas H. Jensen (“Mr. Jensen”), the Company’s Chief Executive Officer.…

Filed Jun 2, 2026Accepted Jun 2, 2026, 5:10 PM EDTCIK 1860657Accession 0001213900-26-064278
Share

Company context

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is developing stenoparib, a novel PARP/tankyrase inhibitor for patients with advanced ovarian cancer, and is using its proprietary DRP® technology to develop a companion diagnostic designed to identify patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s principal operations are located in Denmark, and its U.S. business address is in Florida. For more information, visit www.allarity.com.

Current securities

Recent company filings

  1. Other EventsOct 1, 2026
  2. Other EventsSep 29, 2026
  3. Other EventsSep 16, 2026
  4. Other EventsSep 14, 2026
  5. Results of Operations and Financial ConditionAug 14, 2026

Disclosure sections

Items 5.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02(e) As previously disclosed, effective June 1, 2024, Allarity Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Management Services Agreement (the “Original MSA”) with Ljungaskog Consulting AB, a Swedish limited liability company (the “Consultant”), owned and managed by Thomas H. Jensen (“Mr. Jensen”), the Company’s Chief Executive Officer. Effective as of June 1, 2026 (the “A&R Effective Date”), the Company entered into an Amended and Restated Management Services Agreement (the “A&R MSA”) with the Consultant. The A&R MSA amends and restates the Original MSA in its entirety. Except as described below, the material terms of the A&R MSA are substantially consistent with the material terms of the Original MSA previously disclosed by the Company. Base Compensation and Bonus. Under the A&R MSA, the Monthly Fee is payable in accordance with Attachment B to the A&R MSA, which provides that the Consultant’s annual base salary for 2026 will be paid 80% in Swedish Krona and 20% in U.S. dollars, equal to SEK 6,000,000 and US$163,043. The A&R MSA eliminates the one-time $100,000 signing bonus provided under the Original MSA. The A&R MSA further provides that the Company shall endeavor to issue new annual bonus performance metrics on or before March 31 of each calendar year and, if no new metrics are issued by that date, the prior calendar year’s bonus performance metrics will apply. The annual bonus will be capped at 60% of the Monthly Fees paid to the Consultant in a calendar year. If earned, any annual bonus is payable on or before March 15 following the end of the applicable calendar year. Termination for Convenience by the Company. The A&R MSA increases the Company’s notice period for a termination for convenience from 15 days to 30 days. In addition, upon a termination by the Company for convenience, the Consultant is entitled to the Accrued Payments and a “Termination Payment” equal to 12 months of the Monthly Fee, payable in semi-monthly installments, subject to the Consultant’s compliance with surviving obligations, execution of a general release of claims, and cooperation with transition matters and Company investigations during the payment period. Under the Original MSA, upon a termination by the Company for convenience, the Consultant was entitled only to the Accrued Payments. Other Termination Changes. The A&R MSA provides that, upon a termination by the Consultant for convenience, the Company may waive all or a portion of the Consultant’s 30-day notice period. The A&R MSA further provides that, upon a termination by the Consultant for Good Reason, the Consultant is entitled to the Accrued Payments plus the Termination Payment, subject to the Consultant’s compliance with surviving obligations and execution of a general release of claims. Under the Original MSA, upon a termination for Good Reason, the Consultant was entitled to the Accrued Payments plus an additional nine months of the Monthly Fee, subject to similar release and continuing-obligation conditions. Additional Provisions. The A&R MSA adds provisions addressing Section 409A and Section 280G of the Internal Revenue Code, in each case if the Consultant is subject to federal income taxation in the United States at the applicable time. The foregoing description of the A&R MSA does not purport to be complete and is qualified in its entirety by reference to the full text of the A&R MSA, a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.